SNPHY (Santen Pharmaceutical Co) ROCE %: 23.86% (As of Mar. 2026)

What is Santen Pharmaceutical Co ROCE %?

Santen Pharmaceutical Co SNPHY +5.99% 87 ROCE % is 23.86% as of Mar. 2026. GuruFocus rates SNPHY with a GF Score™ of 87/100 and a GF Value™ of $10.15 (Modestly Overvalued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Santen Pharmaceutical Co's annualized ROCE % for the quarter that ended in Mar. 2026 was 23.86%.

Santen Pharmaceutical Co (OTCPK:SNPHY) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Santen Pharmaceutical Co ROCE % Related Terms

Santen Pharmaceutical Co ROCE % Historical Data

* Premium members only.

The historical data trend for Santen Pharmaceutical Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Santen Pharmaceutical Co ROCE % Chart

Santen Pharmaceutical Co Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Mar26

ROCE %

Get a 7-Day Free Trial

10.22

-1.16

9.11

15.13

14.57

Santen Pharmaceutical Co Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															17.17	10.34	13.15	13.08	23.86

87GF Score

Santen Pharmaceutical Co Ltd SNPHY

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Santen Pharmaceutical Co ROCE % Calculation

Santen Pharmaceutical Co's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2026 )		(A: Mar. 2025 )		(A: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2026 )		(A: Mar. 2025 )		(A: Mar. 2026 )
	=	311.54	/	( ( (2745.764 - 582.573)	+	(2665.905 - 553.734) )	/ 2 )
	=	311.54	/	( (2163.191	+	2112.171)	/ 2 )
	=	311.54	/	2137.681
	=	14.57 %

Santen Pharmaceutical Co's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	501.076	/	( ( (2572.947 - 485.296)	+	(2665.905 - 553.734) )	/ 2 )
	=	501.076	/	( ( 2087.651	+	2112.171 )	/ 2 )
	=	501.076	/	2099.911
	=	23.86 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 23.86% mean?

Santen Pharmaceutical Co (SNPHY) has a ROCE % of 23.86% as of Mar. 2026.

Is Santen Pharmaceutical Co's ROCE % too high?

Santen Pharmaceutical Co's current ROCE % is 23.86%. The Drug Manufacturers industry median ROCE % is 7.00. Santen Pharmaceutical Co's value of 23.86% is 241.1% above this industry median. Overall, Santen Pharmaceutical Co has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Santen Pharmaceutical Co's ROCE % compare to LLY and JNJ?

Santen Pharmaceutical Co's ROCE % of 23.86% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. Santen Pharmaceutical Co's value of 23.86% is 241.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Drug Manufacturers company?

The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Santen Pharmaceutical Co's current ROCE % of 23.86% is 241.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Santen Pharmaceutical Co's current ROCE % is 23.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Santen Pharmaceutical Co stock overvalued right now?

Based on GuruFocus' analysis, Santen Pharmaceutical Co (SNPHY) is currently considered Modestly Overvalued. The stock's GF Value™ is $10.15, compared to a current price of $13.10 — trading 29.1% above its estimated fair value. The current ROCE % is 23.86% and 241.1% above the Drug Manufacturers industry median of 7.00. Santen Pharmaceutical Co's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Santen Pharmaceutical Co (SNPHY), the current ROCE % is 23.86% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Santen Pharmaceutical Co (SNPHY) Overvalued in 2026?

Based on GuruFocus' analysis, Santen Pharmaceutical Co stock appears to be overvalued. The current stock price of $13.10 is trading 29.1% above its estimated GF Value™ of $10.15. GuruFocus considers Santen Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SNPHY:

ROCE %: 23.86%
GF Value™: $10.15 vs. price of $13.10 (29.1% above fair value)
GF Score™: 87/100 with 6 warning signs
Industry Position: 241.1% above the Drug Manufacturers median

No single metric tells the full story. See the SNPHY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Santen Pharmaceutical Co Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies TSE:4528 TSE:4552 TSE:4882 LLY JNJ ABBV XSWX:ROP MRK LSE:AZN XSWX:NOVN OCSE:NOVO B AMGN GILD PFE BMY XPAR:SAN LSE:GSK TSE:4519 XTER:BAYN TSE:4578

Other Exchanges 4536:Japan

Address 4-20 Ofukacho, Grand Front Osaka Tower A, Kita-ku, Osaka Prefecture, Osaka, JPN, 530-8552

Website https://www.santen.com

Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.

87GF Score

Get the complete analysis for SNPHY

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.10

Price

$10.15

GF Value

View SNPHY Analysis

See ROCE % data for all stocks →